DepoCyte (cytarabine)
- Region
- 🇪🇺 EU
- Active substance
- cytarabine
- Company
- Pacira Limited
- Status
- Withdrawn
- Therapeutic area
- Meningeal Neoplasms
- CHMP opinion
- Tue 10 Jul 2018
- EU approval
- Wed 11 Jul 2001
- Application
- EMEA/H/C/000317
- ATC
- L01BC01
- Official record
- www.ema.europa.eu
Indication
Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Vyxeos liposomal (previously Vyxeos) Authorised · Jazz Pharmaceuticals Ireland Limited
Follow DepoCyte
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.